Tetraphase eyes partnership or float to take eravacycline into Phase III
This article was originally published in Scrip
Ahead of fundraising or partnership negotiations to finance Phase III development, Tetraphase Pharmaceuticals unveiled positive Phase II clinical trial data for its lead drug candidate, the intravenous broad-spectrum antibiotic eravacycline (TP-434), in the treatment of complicated intra-abdominal infections (cIAIs) in a trial against ertapenem.
You may also be interested in...
Private Company Edition: Omega raised $438m for its sixth life science fund, while Perceptive and the accelerator Xontogeny partnered on a new $210m venture capital fund. In VC deals, Zentalis and Black Diamond raised $85m each.
The Gilead subsidiary presented updated data at ASH for its first CD19-targeting CAR-T Yescarta and pivotal results for KTE-X19, which it plans to submit for US FDA approval in mantle cell lymphoma this year.
In its first ASH since acquiring Celgene and with competitors coming, Bristol presented pivotal results for liso-cel (JCAR017) that support a year-end US FDA submission as bb2121 nears a first-half of 2020 filing.